The success of Chimeric Antigen Receptor (CAR) T-cell technology in targeting hematologic malignancies has established a robust blueprint for synthetic immunology. However, for researchers in the fields of molecular biology and cellular engineering, the current frontier lies in the repurposing of this modular platform for non-malignant indications. By decoupling the CAR structure from simple...
Romaian 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek